May 14, 2021

DCS-CRD	Listing Compliance
BSE Limited	National Stock Exchange oflndia Ltd.
First Floor, New Trade Wing	Exchange Plaza, 5th Floor
Rotunda Building, Phiroze Jeejeebhoy Towers	Plot No.C/1, 'G'Block, Bandra- Kurla Complex
Dalal Street, Fort Mumbai 400 023	Bandra East Mumbai 400 051
Fax No.2272 3121/2037/2039	Fax No.2659 8237/8238

Stock Code: 543213	Stock Code: ROSSARI

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on Friday, May 14, 2021

Ref.: Intimation under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

With regard to the captioned matter and in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 ("Listing Regulations"), this is to inform you that at the meeting of the Board of Directors of the Company which commenced at 03:00 P.M. and concluded at 06:40 P.M. today i.e. Friday, May 14, 2021, the Board of Directors have Inter alia approved the following:

1. Approval of Audited Financial Results (Standalone and Consolidated) for the financial year ended March 31, 2021, Audited Annual Financial Statements (Standalone and Consolidated) for the financial year ended March 31, 2021 together with Auditor's Report with unmodified opinion thereon. The Audited Financial Results approved by the Board of Directors together with Statutory Auditor Report thereon and a Declaration pursuant to Regulation 33(d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 ("Listing Regulation") as amended and in compliance with SEBI Circular CIR/CFD/CMD/56/2016 dated May 27, 2016 is also enclosed herewith.
1. Recommended a Final Dividend of25% (i.e. Re. 0.50/- per share) on Equity Shares of the Face Value of Rs. 2/- each for the Financial Year ended March 31, 2021 subject to approval by the shareholders at the forthcoming Annual General Meeting the Company. Information regarding Book closure and record date for payment of Final dividend, will be intimated separately.
1. Mr. Manikantan Viswanathan, has resigned from the position of Group Chief Financial Officer of the Company with effect from close of business hours on May 25, 2021 due to personal reasons and the same has been taken on record by the Board of Directors in the meeting held today.

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001 :2015 Certified Company)

Regd. Office : 201 A & B, Ackruti Corporate Park, Next to GE Gardens, LBS Marg, Kanjurmarg (W). Mumbai - 400078. India. T +91-22-6123 3800 F +91-22-2579 6982 Factory: Plot No. 10 & 11, Survey No. 90/1/10 & 90/1/111/1, Kumbharwadi, Village Naroli, Dadra & Nagar Haveli (U.T.), Silvassa - 396 235. India. T 0260 - 669 3000 E [email protected] W www.rossari.com CIN: L24100MH2009PLC194818

The aforesaid Audited Financial results were reviewed by the Audit Committee and subsequently, approved and taken on record by the Board of Directors of the Company at their respective meetings held today i.e. May 14, 2021 .

The aforesaid information will also be available on Company's website at www.rossan.com.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely, For Rossari Biotech Limited

Parul Gupta Company Secretary & Compliance Officer Membership No.: A38895

Encl.: as above

(An ISO 9001 :2015 & 14001:2015 Certified Company)

Regd. Office: 201 A & B, Ackruti Corporate Park, Next to GE Gardens, LBS Marg, Kanjurmarg (W). Mumbai - 400078. India. T +91-22-6123 3800 F +91-22-2579 6982 Factory: Plot No. 10 & 11, Survey No. 90/1/10 & 90/1/111/1 , Kumbharwadi, Village Naroli, Dadra & Nagar Haveli (U.T.), Silvassa - 396 235. India. T 0260 - 669 3000 E [email protected] W www.rossari.com CIN: L24100MH2009PLC194818

Deloitte Haskins & Sells LLP 27" 32" Floor,

Chartered Accountants One International Center, Tower 3, - Senapati Bapat Marg, Elphinstone Road (West) Mumbai, 400 013 Maharashtra, India Tel: +91 22 6185 4000 Fax: +91 22 6185 4001

FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE

TO THE BOARD OF DIRECTORS OF ROSSARI BIOTECH LIMITED

Opinion and Conclusion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2021 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2021 which were subject to limited review by us, both and Year Ended March 31, 2021 of Rossari Biotech Limited tion 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing ii. gives a true and fair view in conformity with the recognition and measurement principles (refer 'Other Matters' section below), included in the accompanying "Statement of Standalone Financial Results for the Quarter ("the Company"), ("the Statement"), being submitted by the Company pursuant to the requirements of Regula amended ("the Listing Regulations").

(a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2021:

Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2021

With respect to the Standalone Financial Results for the quarter ended March 31, 2021, based on our r section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2021, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. eview conducted as stated in paragraph (b) of Auditor's Responsibilities

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2021

s Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2021 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion. We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor' the Institute of Chartered Accountants of India ("the ICAI") together with the ethical the !CAi's Code of Ethics. We believe

Management's Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Compa Standalone Financial Results for the year ended March 31, 2021 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2021 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error. ny's Board of Directors and has been approved by them for the issuance. The

In preparing the Standalone Financial Results, the Board of Directors are responsible for matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. assessing the Company's ability, to continue as a going concern, disclosing, as applicable,

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

ities Auditor's Responsibil

(a) Audit of the Standalone Financial Results for the year ended March 31, 2021

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2021 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. •
Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of • expressing an opinion on the effectiveness of the Company's internal control.
Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors. •
Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations. •
of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty in the Statement or, if such disclosures are inadequate, to modify our opinion. Our report. However, future events or conditions may cause the Company to cease to continue as a going concern. • Conclude on the appropriateness of the Board of Directors' use of the going concern basis exists, we are required to draw attention in our auditor's report to the related disclosures conclusions are based on the audit evidence obtained up to the date of our auditor's
Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation. •

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Standalone Financial Results for the quarter ended March 31, 2021

We conducted our review of the Standalone Financial Results for the quarter ended March by the ICAI. A review of interim financial information consists of making inquiries, primarily analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 31, 2021 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued of the Company's personnel responsible for financial and accounting matters, and applying

Other Matters

The Statement includes the results for the Quarter ended March 31, 2020, being the balancing figure of audited figures for the year ended March 31, 2020, and figures for nine months ended December 31, 2019, which were subject to special purpose audit by us. •
The statement includes the results for the Quarter ended March 31, 2021, being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. •

Our report on the Statement is not modified in respect of these matters.

For Deloitte Haskins & Sells LLP Chartered Accountants 117366W/W-100018) (Firm's Registration No.

Manoj H. Dama (Partner) (Membership No. 107723) (UDIN: 21107723AAAAHV5483)

ROSSARI BIOTECH LIMITED ROSSAAI

(AN ISO9001:2005 & 14001:2015 Certified Company) ~ -•comp 1

Regd. Office : 201 A & B, 2 nd Floor, Akruti Corporate Park, L.B.S. Marg, Next to GE Gardens, Kanjurmarg {W) Mumbai -400078 T +91-22-6123 3800 F +91-22- 25796982 E [email protected] W www.rossari.com CIN: L24100MH2009PLC194818

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND VEAR ENDED 31ST MARCH, 2021

	Particulars		Quarter ended		Rs. In mi/lionsVear Ended
		31st March,	31st December,	31st March,	31st March,	31st March,
		2021Refer Note 4	2020	2020	2021	2020
I	INCOME		Unaudited	Refer Note 4	Audited	Audited
	Revenue from operations	2,014.82	2,057.57	1,595.48	6,904.14
	Other Income	25.40	11.04	19.88	102.09	6,000.94
	Total Income	2,040.22	2,068.61	1,615.36	7,006.23	36.316,037.25
II	EXPENSES
	Cost of materials consumed	1,320.27	1,289.26	962.74	4,338.78	3,692.64
	Purchase of stock-in-trade	67.38	182.48	-	249.86	-
	Changes in inventories of finished goods and work-	(8.94)	(74.93)	26.07	(72.21)	24.38
	in-progress
	Employee benefits expense	94.56	88.11	95.12	366.60	371.34
	Finance costs	8.04	3.62	10.11	29.92	36.78
	Depreciation and amortization expenses	69.36	58.61	46.01	220.74	168.52
	Other expenses	197.37	248.56	269.91	812.56	862.52
	Total Expenses	1,748.04	1,795.71	1,409.96	5,946.25	5,156.18
Ill	Profit before exceptional items and tax [1-11)	292.18	272.90	205.40	1,059.98	881.07
IV	Exceptional items		-	-		-
V	Profit before tax [Ill-IV)	292.18	272.90	205.40	1,059.98	881.07
VI	Tax Expense
	Current tax charge	81.83	67.53	53.53	275.30	238.01
	Deferred tax charge/{credit)	(3.64)	{1.06)	0.02	{6.34)	{12.16)
	Total Tax Expense	78.19	66.47	53.55	268.96	225.85
VII	Profit after tax [V-VI)	213.99	206.43	151.85	791.02	655.22
VIII	Other comprehensive income
A	Items that will not be reclassified to profit or loss
	Remeasurements of the defined benefit plans	3.78	(0.70)	{2.29)	1.67	(2.81)
ii	Income tax relating to items that will not bereclassified to profit or loss	(0.94)	0.17	0.58	{0.42)	0.56
B	Items that will be reclassified subsequently to profitor loss	-	-	-	-	-
	Total other comprehensive income/{Loss)	2.84	(0.53)	(1.71)	1.25	(2.25)
IX	Total comprehensive income (VII + VIII)	216.83	205.90	150.14	792.27	652.97
	Paid up equity share capital (Face value of Rs 2 per	103.86	103.86	101.51	103.86	101.51
	share)Other equity				3,940.58	2,733.23

X	Earnings per equity share (in Rs.)
	Basic	4.11	3.9'!!	3.11	15.34	13.48
	Diluted*Not annualized	4.ld'	3.95	3.0~	15.25	13.28

ROSSARI BIOnCH UMlnD

Standalone Balance ShHt as at 31st March, 2021·

	Particulars
		As at31st March, 2021Audited	As at31st March, 2020Audited
ASSETS
	NON-CURRENT ASSETS
(a)	Property, Plant and Equipment	1,600.88	817.55
(Ь)	Right of Use Assets	69.38	70.15
(c)	Capital Work-in-Progress	3.19	217.51
(d)	Intangible Assets	37.27	47.66
(e)	Financial Assets
	(i) Investments	92.53	46.50
	(ii) Other Financial Assets	205.48	3.96
(f)	Income Tax Assets (Net)	21.19	15.49
${g}$	Deferred Tax Assets (Net)	0.52	÷.
			237.06
(g)	Other Non-current Assets	18.01
	TOTAL NON-CURRENT ASSETS	2,048.45	1,455.88

	CURRENT ASSETS
(a)	Inventories	885.21	581.70
(b)	Financial Assets
	(i) Investments		105.60
	(ii) Trade Receivables	1,373.22	938.06
	(III) Cash and Cash Equivalents	148.31	291.90
	(iv) Bank Balances other than (iii) above	711.51	980.17
	$(v)$ Loans	27.81	11,48
	(v) Other Financial Assets	28.47	41.44
(c)	Other Current Assets	220.61	276.63
	TOTAL CURRENT ASSETS	3,395.14	3,226.98

	TOTAL ASSETS	5,443.59	4,682.86

	EQUITY AND LIABILITIES
EQUITY
(a)	Equity Share Capital	103.86	101.51
(b)	Other Equity	3,940.58	2,733.23
	TOTAL EQUITY	4,044.44	2,834.74

	LIABILITIES
	NON-CURRENT LIABILITIES
(a)	Financial Liabilities
	Borrowings		339.60
(c)	Provisions	9.87	16.26
(d)	Deferred Tax Liability (Net)		5.40
	TOTAL NON-CURRENT LIABILITIES	×9.87	361.26


	CURRENT LIABILITIES
(a)	Financial Liabilities
	(i) Borrowings		270.52
	(il) Trade Payables
	a) total outstanding dues of Micro Enterprises and Small	150.54	51.28
	Enterprises
	b) total outstanding dues of Creditors other than MicroEnterprises and Small Enterprises	1,085.88	918.59
	(iii) Other Financial Liabilities	104.96	161.87
(b)	Other Current Liabilities	32.61	41.33

(c)	Provisions	6.95	6.66
(d)	Current Tax Liabilities (Net)	8.34	36.61
	TOTAL CURRENT LIABILITIES	1,389.28	1,486.86

	TOTAL EQUITY AND LIABILITIES	5,443.59	4,682.86

ROSSARI BIOTECH LIMITED

Standalone Statement of Cash Flow for the year ended 31st March, 2021

		Rs. In millions
	Particulars	For the year ended31st March, 2021	For the year ended 31stMarch 2020
		Audited	Audited
A	Cash flows from operating activities
	Profit before tax	1,059.98	881.07
	Adjustments for:
	Depreciation and amortisation expenses	220.74	168.52
	(Profit)/Loss on disposal of property, plant and equipment	(4.32)	0.42
	Provision for expected credit loss	0.15	0.60
	Provision/Write off of doubtful advances		1.20
	Share-based payments expenses	15.30	4.53
	Written down of Inventory to net realisable value	4.71	4.93
	Finance Costs	29.92	36.78
	Dividend Income	(32.71)	(0.73)
	Interest Income	(49.59)	(14.58)
	Net loss iilrising on financial assets measured at fair value
	through profit/ loss	0.01	0.21
	Deemed income on investment	(0.12)	(0,31)
	Net foreign exchange loss/(gain)	(0.01)	0,02
	Operating profit before working capital changes	1,244.06	1,082.76
	Changes in:
	Trade Receivables and other assets	(351.38)	(217.88)
	Inventories	(308.21)	(37.65)
	Trade Payables and other liabilities	255.77	(58.27)
	Cash generated from Operations	830.24	758.96
	Income taxes paid (net of refunds)	(309.28)	(201-48)
	Net cash flows generated from operating activities	520.96	557.48

B	Cash flows from investing activities
	Net (Investment)/ redemption of Mutual Funds	105,60	(105,60)
	Payments to acquire non current investment- joint venture		(43.93)
	Payments to acquire non current investment - subsidiary	(45.91)
	Loans given to subsidairy company	(32.50)
	Loans repaid by subsidiary company	8.80
	Dividend Received	32.71	0.73
	Interest Received	42,34	13.00
	Payments to acquire property, plant and equipment (including
	Capital work in progress) and intangible assets	(579.87)	(759.71)
	Proceeds from sale of property, plant and equipment and
	intangible assets	21.86	0.83
	(lncrease)/Decrease in bank balances not considered as cash and
	cash equivalents (net)	76.99	(977.79)
	Net cash flow used in investing activities	(369.99)	(1,872.47)

C	Cash flows from financing activities
	Proceeds/ (Repayment) from short term borrowing (net)	(270.52)	249.39
	Repayment of long-term borrowings	(398.77)	(12.58)
	Repayment of loans from related parties		(30.15)
	Proceeds from long-term borrowings		403.67
	Interest paid	(26.41)	(34.21)
	Proceeds from Issue of equity shares (net of share issue expenses)	426.53	1,000.00
	Dividend paid on equity shares (including Dividend distribution
	tax)	(25.38)	(26.48)
	Net cash flow generated from / (used in ) financing activities	(294.54)	1,549.64

	Net increase/(decroase) in cash and cash equivalents (A+B+C)	(143.60)	234.66
	Opening Cash and cash equivalents	291.90	57.26
	Effects of exchange rate changes on the balance of cash and
	cash equivalents held in foreign currencies	0.01	(0.02)
	Closing Cash and cash equivalents	148.31	291.90

Notes:

The above Cash Flow Statement has been prepared under the "Indirect Method" set out in Accounting Standard (Ind AS 7) - Statement of Cash flow. ~ L

Notes:

1 The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 14th May, 2021.
2 The financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
3 The Company is mainly engaged in the business of manufacturing of Specialty Chemicals for Textile, Home and Personal Care, and Performance Chemicals industries. There are no reportable segments in accordance with IND AS 108 - Operating Segments.
4 The Statement includes the results for the quarter ended 31st March, 2020 being the balancing figure of audited figures for year ended 31st March, 2020 and figures for nine months ended 31st December 2019, subjected to special purpose audit by the statutory auditors. The statement further includes figures for the quarter ended 31st March, 2021 being the balancing figure of the audited figures for the year ended 31st March, 2021 and figures for the nine months ended 31st December, 2020 subjected to limited review.
5 During the year ended on 31st March, 2021, the Board of Directors at its meeting held on 23rd March, 2021, interalia approved the issue of 3,012,046 equity shares on preferential basis for cash consideration . Subsequent to year ended 31st March, 2021, the shareholder of the Company at its Extra Ordinary General meeting held on 17th April, 2021 has approved issue of 3,012,046 shares of face value of Rs. 2 each on preferential basis at Rs. 996 per share aggregating to Rs. 3000.00 million to certain parties. The allotment of the shares of the Company has been completed on 21st April, 2021.
6 The Board of Directors have recommended final dividend of Rs. 0.50 per share (25 percent of the face value of the equity share of face value of Rs. 2 each} for the financial year ended 31st March, 2021.
7 The Indian parliament has approved the Code on Social security, 2020 ("the Code") which, inter alia, deals with employee benefits during employment and post employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified and the rules for quantifying the financial impact are also yet to be issued. In view of this, the impact of the change, if any, will be assessed and recognised post notification of the relevant provisions.
8 Pursuant to the lockdowns by the central and state government authorities to contain the spread of COVID-19 outbreak, the Company's operations and financial results for the year have been impacted. The operations gradually resumed in a phased manner with requisite precautions during the year ended 31st March, 2021. The results for the year are therefore not comparable with those for the previous periods. The Company has considered relevant internal and external sources of information and its impact on the recoverability of financial and non-financial assets while preparation of these financial results. However, the actual impact may be different from that estimated as at the date of approval of these financial results.

For ROSSARI BIOTECH LIMITED

Executive Chairman DIN:00149205

Place : Mumbai Date :14th May, 2021 ~

Chartered Accountants One International Center, Tower3,2732"Floo Senapati Bapat Marg, Elphinstone Road (West) Mumbai, 400 013 Maharashtra, India Tel: +91 22 6185 4000 Fax: +91 22 6185 4001